BioCentury
ARTICLE | Clinical News

BioLineRx gains on updated BL-1020 data

October 10, 2012 1:18 AM UTC

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) gained $0.32 (11%) to $3.35 on Tuesday after reporting updated data from the Phase IIb EAGLE trial of BL-1020 to treat schizophrenia. A new analysis of a subset of patients for whom the time of day for administration of the Brief Assessment of Cognition in Schizophrenia (BACS) test was consistent between visits showed that BL-1020 significantly improved cognitive function from baseline by 97% compared to placebo and by 57% compared to risperidone. BioLineRx said that patients with schizophrenia are known to have disturbed circadian rhythms that can affect cognitive functioning over the course of the day. ...